Adverse Event Reporting to IRBs – Best Practices to Follow
Abstract:The Food and Drug Administration (FDA) has issued guidelines for adverse event reporting because adverse event reports were found to be inhibiting, rather than enhancing, the ability of IRBs to protect the human subjects.
This article describes the best practices to be followed in order to comply with the FDA's new guidelines on adverse event reporting to IRBs.
Trending Compliance Trainings
Sterile Filtration of Pharmaceutical Products - Validation and Regulatory Requirements
By - Roger Cowan
On Demand Access Anytime
By - Roger Cowan
On Demand Access Anytime
FFIEC BSA/AML Examination Manual: What Compliance Officers Really Need to Know?
By - Doug Keipper
On Demand Access Anytime
By - Doug Keipper
On Demand Access Anytime
Technical Writing for the Pharmaceutical, Medical Device and Biotech Industries
By - Joy McElroy
On Demand Access Anytime
By - Joy McElroy
On Demand Access Anytime
Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
By - Michael Ferrante
On Demand Access Anytime
You Recently Viewed
